Park Square is pleased to announce the placement of Jose Trevejo, M.D., Ph.D. as Chief Medical Officer and Bigyan Bista, Ph.D. as Senior Vice President and Head of Business Strategy and Development at Enveda Biosciences. Enveda is a pioneering biotechnology company using AI to translate the world’s novel chemistries into new medicines. 

Dr. Trevejo joins Enveda following a string of recent successes, most recently at Tarsus Pharmaceuticals, where he helped lead the FDA approval and launch of a category-creating ophthalmic treatment along with multiple positive Phase 2 readouts. He brings more than fifteen years of leadership and drug development expertise to Enveda, spanning the entire clinical development process from proof-of-concept through approval and early commercialization. Dr. Trevejo has worked across numerous therapeutic areas, including GI, dermatology, ophthalmology, infectious diseases, cardiac and metabolic diseases, as well as immunology. Dr. Trevejo received his M.D. and Ph.D. at the Cornell-Rockefeller-Sloan Kettering Tri-Institutional M.D./Ph.D. Program and completed his residency and specialty training at Harvard Medical School. 

Dr. Bista brings a diverse blend of scientific and business experience, having started his career as a scientist and moved into roles in consulting, strategy, and investing. He most recently served as an Investor at Rock Springs Capital, a leading healthcare and life science investment fund. Prior, he held strategy roles at AstraZeneca and Clarion Healthcare. Dr. Bista earned his Ph.D. in Cancer Biology from the Massachusetts Institute of Technology.